Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...
Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...
The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...
Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...
Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...